Ardelyx, Inc. (ARDX) Stock Price & Analysis
Ardelyx, Inc. (ARDX) rose 1.08% to USD 5.6 as of June 10, 2026 at 02:17 UTC, according to Nexqual real-time market data.
ARDX last closed at USD 5.54; the session ranged USD 5.48–5.72 on volume of 2,975,133 shares. Market capitalization is $1.38B, with a 52-week range of USD 3.49–8.4 (NGM). Source: Nexqual, June 10, 2026 at 02:17 UTC.
Key Statistics (as of June 10, 2026 at 02:17 UTC)
| Price | USD 5.6 |
|---|---|
| Change | ▲ 1.08% (up) |
| Previous Close | USD 5.54 |
| Open | USD 5.65 |
| Day Range | USD 5.48 – 5.72 |
| 52-Week Range | USD 3.49 – 8.4 |
| Volume | 2,975,133 shares |
| Market Cap | $1.38B |
| Exchange | NGM |
Technical Analysis (ARDX)
Nexqual's technical model rates ARDX "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:17 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.27 (neutral) |
| vs SMA50 | Below (USD 6.18) |
| MACD | -0.23 (negative) |
Analyst Ratings (ARDX)
Wall Street analysts rate ARDX "Strong Buy" based on 9 analysts, with a mean price target of USD 16.33 (range USD 13–19), per Nexqual as of June 10, 2026 at 02:17 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 16.33 |
| High Target | USD 19 |
| Low Target | USD 13 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (ARDX)
| Next Earnings Date | 2026-04-30 |
|---|---|
| EPS Estimate | USD -0.04 |
| Revenue Estimate | $128.24M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.15 vs est -0.14 ▼ miss |
| 2025-12-31 | USD 0 vs est 0.01 ▼ miss |
| 2025-09-30 | USD 0 vs est -0.07 ▲ beat |
| 2025-06-30 | USD -0.08 vs est -0.14 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:17 UTC.
Financials & Fundamentals (ARDX)
| Total Revenue | $427.68M |
|---|---|
| Revenue Growth (YoY) | +27.50% |
| Gross Margin | +74.56% |
| Operating Margin | -34.71% |
| Profit Margin | -13.58% |
| ROE | -39.46% |
| Debt / Equity | 157.53 |
| Current Ratio | 3.49 |
| Total Cash | $238.07M |
| Total Debt | $234.13M |
| Free Cash Flow | $86,375 |
Source: Nexqual, June 10, 2026 at 02:17 UTC.
Financial Health Score (ARDX)
Nexqual rates Ardelyx, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:17 UTC.
| Growth | Strong — Revenue +22% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 75%, operating -35% |
| Balance Sheet | Weak — $238M cash vs $234M debt, net cash position |
| Cash Flow | Mixed — FCF $86K, slim 0.0% margin |
| Efficiency | Critical — ROE -39%, ROA -5.1% |
Ownership (ARDX)
| Insider Ownership | +3.19% |
|---|---|
| Institutional Ownership | +70.66% |
| Shares Outstanding | 247.03M |
| Float | 219.85M |
| Short % of Float | +10.25% |
Source: Nexqual, June 10, 2026 at 02:17 UTC.
Leadership (ARDX)
Ardelyx, Inc. is led by Michael G. Raab (age 60), President, CEO & Director, per Nexqual as of June 10, 2026 at 02:17 UTC.
| President, CEO & Director | Michael G. Raab (age 60) |
|---|---|
| Chief Financial Officer | Sue Hohenleitner (age 54) |
| Vice President of Corporate Communications & Investor Relations | Caitlin Lowie |
Major Backers & Investors (ARDX)
Notable institutional backers of Ardelyx, Inc. include Millennium Management, Janus Henderson Group PLC, Nomura Asset Management International Inc, according to Nexqual as of June 10, 2026 at 02:17 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Millennium Management | 7.22% |
| Janus Henderson Group PLC | 3.39% |
| Nomura Asset Management International Inc | 3.31% |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 2.7% |
| Two Sigma Investments, LP | 1.73% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.81% |
| BlackRock | 11.64% |
| State Street | 8.98% |
| Geode Capital | 2.43% |
| Nuveen | 2.12% |
Source: Nexqual, June 10, 2026 at 02:17 UTC.
From Ardelyx, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
- The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.
- Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AKBA | Akebia Therapeutics, Inc. | USD 0.92 | ▼ 1.6% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.72 | ▲ 5.52% |
| CTMX | CytomX Therapeutics, Inc. | USD 2.98 | ▼ 0.67% |
| TGTX | TG Therapeutics, Inc. | USD 43.37 | ▲ 7.99% |
| KALA | KALA BIO, Inc. | USD 2.35 | ▲ 14.08% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:17 UTC. This page is informational and not investment advice.